Valsartan
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Angiotensin II Receptor Blockers | Valsartan | 80-320mg PO Q24H | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
435 | 13 | 9.4 | N/A | 95 | 0.23 | N/A | 0 (N/A) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00177
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
- Leidig M, Delles C, Kuchenbecker C, et al. Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis. Clinical Drug Investigation. 2001;21(1):59-66.